Compare Ascendis Pharma A/S (ASND) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Nuscale Power Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Nuscale Power Corporation trades at $8.91 (market cap $3.13B). The key difference: Ascendis Pharma A/S is far larger — about 5.7× Nuscale Power Corporation's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| ASND | SMR | |
|---|---|---|
Market Cap | $17.74B | $3.13B |
Sector | Health | Utilities |
52-Week High | $277.18 | $53.43 |
52-Week Low | $163.32 | $8.76 |
Enterprise Value | $18.11B | $2.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
NuScale Power (SMR) trades at $9.03, showing no daily change. The stock exhibits a bearish technical trend with significant negative profitability metrics, including a net income margin of -2,066.55% and consecutive quarterly earnings misses. Despite these challenges, analyst consensus remains optimistic with a $13.00 price target, citing the company's first-mover advantage in small modular nuclear reactors and potential long-term growth tied to AI-driven power demand.
The outlook for SMR balances high-risk, high-reward potential. Opportunities include certified SMR technology and strategic partnerships, but risks are substantial: persistent operating losses, negative cash flow from operations, and uncertainty around commercial reactor sales. Investors face volatility with the stock near 52-week lows, requiring careful assessment of execution capability versus speculative growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
